LIFERIVER(SH:688317) Tong Hua Shun Cai Bao·2025-04-29 10:20Financial Performance - The company reported a basic earnings per share of -0.0800 yuan for Q1 2025, a decrease of 157.14% compared to 0.1400 yuan in Q1 2024 [1] - The net profit for Q1 2025 was -0.16 billion yuan, representing a decline of 159.26% from 0.27 billion yuan in Q1 2024 [1] - The operating revenue decreased by 37.25% to 0.32 billion yuan in Q1 2025 from 0.51 billion yuan in Q1 2024 [1] - The return on equity was -0.44% in Q1 2025, down from 0.70% in Q1 2024, marking a decline of 162.86% [1] Shareholder Information - The top ten unrestricted shareholders hold a total of 86.4869 million shares, accounting for 45% of the circulating shares, with a decrease of 213,000 shares compared to the previous period [2] - Shanghai Zhijiang Pharmaceutical Co., Ltd. remains the largest shareholder with 64.9696 million shares, representing 33.81% of the total share capital, unchanged from the previous period [3] - Other notable shareholders include Ningbo Kangfeidengsi Investment Management Partnership and GF Value Core Mixed A, both of which have not changed their holdings [3] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares in this period [3]